Literature DB >> 9193430

Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study.

J G van der Bom1, P de Knijff, F Haverkate, M L Bots, P Meijer, P T de Jong, A Hofman, C Kluft, D E Grobbee.   

Abstract

BACKGROUND: Impaired fibrinolytic capacity, as assessed by euglobulin clot lysis time or plasma concentration of fibrinolytic parameters, has been associated with an increased risk of myocardial infarction (MI). We studied the association of a polymorphism in the gene for TPA and of plasma concentrations of TPA (antigen and activity) with the prevalence of MI. METHODS AND
RESULTS: A case-control study was performed. Subjects with a history of MI (n = 121) and controls (n = 250) were drawn from the Rotterdam Study, a population-based cohort study of 7983 subjects > or = 55 years old. We determined TPA antigen and activity in plasma and genotyped all subjects for the Alu repeat insertion/deletion polymorphism in intron h in the TPA gene. Homozygosity for the insertion was associated with twice as many cases of MI as was homozygosity for the deletion (odds ratio, 2.24; 95% CI, 1.11-4.50). TPA antigen was positively associated with the risk of MI; compared with that in the lowest quartile, the relative risks (odds ratio) in the second, third, and upper quartiles were 1.7 (CI, 0.9-3.3), 2.3 (1.2-4.4), and 2.0 (1.0-3.8), respectively. When adjusted for body mass index, HDL and total cholesterol, systolic and diastolic blood pressures, and current smoking, the risk associated with TPA antigen concentration was attenuated. Increased concentrations of TPA activity tended to be associated with an increased risk of MI.
CONCLUSIONS: This study provides evidence for an independent association of the insertion allele of the insertion/deletion polymorphism in the TPA gene with nonfatal MI. Increased TPA antigen is associated with an increased risk of MI; however, this association was not independent of cardiovascular disease risk factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9193430     DOI: 10.1161/01.cir.95.12.2623

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  The association between thrombophilic gene mutations and recurrent pregnancy loss.

Authors:  Ahmad Poursadegh Zonouzi; Nader Chaparzadeh; Saeid Ghorbian; Mahzad Mehrzad Sadaghiani; Laya Farzadi; Alieh Ghasemzadeh; Taiebeh Kafshdooz; Masoud Sakhinia; Ebrahim Sakhinia
Journal:  J Assist Reprod Genet       Date:  2013-08-29       Impact factor: 3.412

3.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

4.  Proteomic biomarkers of sleep apnea.

Authors:  Aditya Ambati; Yo-El Ju; Ling Lin; Alexander N Olesen; Henriette Koch; Julien Jacques Hedou; Eileen B Leary; Vicente Peris Sempere; Emmanuel Mignot; Shahrad Taheri
Journal:  Sleep       Date:  2020-11-12       Impact factor: 5.849

5.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

6.  A Common Calibrator Does Not Secure Harmonisation of Commercial t-PA and PAI-1 Antigen Measurements.

Authors:  Moniek P M de Maat; Jorgen Gram; Jorgen Jespersen; Cornelis Kluft
Journal:  EJIFCC       Date:  2001-07-22

Review 7.  Fibrinolytic function and coronary risk.

Authors:  I Juhan-Vague; P Morange; M Christine Alessi
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

8.  Is tissue-plasminogen activator gene polymorphism a risk factor for venous thromboembolism in every population?

Authors:  I Kivilcim Oguzulgen; Numan Ekim; Ferda Oner Erkekol; Buket Altinok; Nejat Akar
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

9.  Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction.

Authors:  Joshua W Knowles; Huijan Wang; Haruka Itakura; Audrey Southwick; Richard M Myers; Carlos Iribarren; Stephen P Fortmann; Alan S Go; Thomas Quertermous; Mark A Hlatky
Journal:  Am Heart J       Date:  2007-12       Impact factor: 4.749

10.  4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.

Authors:  Muammer Karadeniz; Mehmet Erdogan; Afig Berdeli; Fusun Saygili; Candeger Yilmaz
Journal:  J Assist Reprod Genet       Date:  2007-07-28       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.